Population pharmacokinetics and dosing optimization of imipenem in Chinese elderly patients

Front Pharmacol. 2025 Jan 9:15:1524272. doi: 10.3389/fphar.2024.1524272. eCollection 2024.

Abstract

Objectives: To assess the pharmacokinetics and pharmacodynamics of imipenem in a retrospective cohort of hospitalized Chinese older patients.

Methods: A population pharmacokinetic (PPK) model was constructed utilizing a nonlinear mixed-effects modeling approach. The final model underwent evaluation through bootstrap resampling and visual predictive checks. Additionally, a population pharmacokinetic and pharmacodynamic analysis was conducted employing Monte Carlo simulations to investigate the impact of commonly used dosing regimens (0.25 g every 6 h, 0.5 g every 6 h, 0.5 g every 8 h, 1 g every 6 h, 1 g every 8 h, and 1 g every 12 h) on the likelihood of achieving the target therapeutic outcomes.

Results: A total of 370 observations available from 142 patients were incorporated in the PPK model. A two-compartment PPK model with linear elimination best predicted the imipenem plasma concentrations, with the creatinine clearance as a significant covariate of clearance. Typical estimates for clearance, inter-compartmental clearance, central and peripheral volume were 13.1 L·h-1, 11.9 L·h-1, 11.7 L, 29.3 L, respectively.

Conclusion: The pharmacokinetics of imipenem in elderly patients were effectively characterized by the established PPK model, which includes creatinine clearance as a key covariate. This research will enhance our understanding of imipenem elimination and support precision dosing in this patient demographic.

Keywords: Monte Carlo; dosing optimization; elderly patients; imipenem; population pharmacokinetics.

Grants and funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was supported by Jiangsu Research Hospital Association for Precision Medication (Grant No. JY202231) and Nanjing Pharmaceutical Association Changzhou Siyao Hospital Pharmaceutical Research Fund project (Grant No. 2022YX006).